IT HAS BEEN proposed that peptidergic nerves in the heart and around blood vessels have a role in the regulation of the cardiovascular system. Calcitonin gene-related peptide (CGRP) is a 37-amino acid peptide resulting from alternative processing of the RNA during calcitonin gene expression.1 Its existence was first predicted by analysis of a new RNA in a rat cell line and subsequently a similar peptide was isolated from human medullary carcinoma of thyroid and sequenced by FAB spectroscopy.2 CGRP is a potent vasodilator in vitro and in vivo in the rat. [3] [4] [5] It has also been demonstrated that CGRP will dilate human epicardial coronary arteries in vivo.6 Extensive histo-chemical studies in the rat and guinea pig have shown a widespread distribution of CGRP and substance P (SP) in the perivascular nerves and atrium, and in the conducting tissue of the heart.7 8 SP is an 11-amino acid peptide that was first isolated over 50 years ago.9 In both central and peripheral nerves it is found to colocalize with CGRP. 8 10 Studies using extracted and synthetic SP have shown it to be a potent arterial dilator in man but the duration of the responses has not been studied in any detail."11 12 CGRP and SP will each produce a fall in diastolic blood pressure and an associated tachycardia when infused systemically in man.13' 14 The systemic infusion of each of these peptides suggested that while of comparable potency as vasodilators, the rates of onset and offset of effects were different. However, the blood pressure effects of a systemic infusion of a vasodilator are masked in young fit people by prompt baroreflex responses, resulting in norepinephrine release and an increased heart rate, and the systolic blood pressure is thus maintained.15 For this reason, we have now compared the effects of CGRP with those of SP on two CIRCULATION THERAPY AND PREVENTION-PHARMACOLOGY different vascular beds in man: the forearm resistance vessels and the superficial veins of the hand. By performing the studies with doses of peptides that were sufficiently low that no systemic effect would be expected, we were able to study the rates of onset and offset of the local responses. The effects of CGRP and SP on forearm resistance vessels were assessed by measuring forearm blood flow in response to a brachial artery infusion of peptide. The effect of the peptides on the superficial veins of the hand was assessed by measuring venous diameter during infusion of the peptide, either at rest or when the vein was preconstricted with norepinephrine or by the single deep breath reflex.
Methods
Subjects. The brachial artery infusion studies were performed on eight normal individuals, all men, four of whom participated in both studies so that there were six studies of dose-response for each peptide. Three subjects also received two prolonged infusions, one of each peptide at one dose, and four also participated in the study on Dose response. Figure 4 shows the effect of the incremental increases in infusions of CGRP or SP on forearm blood flow. Forearm blood flow increased during infusion of CGRP from a mean value of 3.28 ± 0.56 to 9.08 + 2.12 ml/min/100 ml at the highest dose of 10 pmol/min (a rise of 177 ± 75%). Infusion of SP caused a dose-dependent increase in forearm blood flow of from 2.18 ± 0.39 to 6.41 + 1.42 ml/min/10( ml at 1.5 pmol/min (a rise of 198 ± 50%). Thus, the dose of SP required to produce equivalent increases in forearm blood flow was approximately one-tenth of the dose of CGRP. The dose-dependent increase in forearm blood flow was significant (p < .05) for CGRP at doses of greater than 1.25 pmol/min and for SP infusion at doses greater than 0.5 pmol/min. Duration of effect. When the infusion of CGRP was replaced with control vehicle solution, the increased blood flow returned slowly toward the starting value (figure 5). The Effect of coinfusion. In this study, the initial response to incremental doses of SP was similar to that found in the first study, with flow increasing from 5.5 ±t 1.4 to 11.8 ±--2.8 ml/min/100 ml at 1 pmol/min of SP (n = 3). After the flow returned to basal levels, the infusion of CGRP (3.75 pmol/min) increased blood flow to 8.4 ±+ 2.3 ml/min/100 ml. SP infused with CGRP pro- ml/min/100 ml at the highest dose of 1 pmol/min, this increase being slightly greater than that achieved with the initial response to SP alone (figure 7). figure 3) .
However, the effect of SP was of much shorter duration and within 30 sec of stopping the infusion of SP, blood flow had returned to basal levels. The reasons for this difference in duration of the effects of the two peptides is unknown, but might be due to differences in the rate of metabolism of the peptides within the local tissues or differences in the rate of dissociation of agonist and receptor.
Both resistance vessels and veins show tachyphylaxis to SP. Others have shown that during systemic infusion of SP in dogs and in man the maximum effect is achieved rapidly, followed by a gradual decline in the degree of hypotension and tachycardia.13 17 34 Coexistence of the two peptides has also been shown in cell bodies in the dorsal root ganglia and nodose ganglia.32 Nerve fibers positive for both peptides are seen in the celiac, superior cervical myenteric, and autonomic ganglia.5 A similar distribution of nerve fiber networks containing each peptide has been demonstrated in the walls of rodent blood vessels8 and the colocalization of CGRP and SP in the perivascular nerve networks has been confirmed in the cerebral arteries of the rat by double-staining techniques.10 The fibers that contain CGRP and SP are largely from primary sensory afferent nerves, since they are sensitive to capsaicin, a neurotoxin selective for C and AS fibers.8 A few fibers appear more resistant to the neurotoxin and, although this may be a dose-dependent phenomenon, it could also suggest the presence of CGRP in fibers subserving different functions.
The presence of a lon-g-and a short-acting vasodilator in the forms of CGRP and SP would appear an attractive option, giving good 
